The Walton Centre for Neurology and Neurosurgery NHS Trust, Lower Lane, Liverpool, L9 7LJ, UK.
J Neurol. 2017 Nov;264(11):2330-2344. doi: 10.1007/s00415-017-8445-8. Epub 2017 Mar 13.
The evolution of neuromyelitis optica spectrum disorder (NMOSD) from a rare, incurable and misunderstood disease with almost universally poor outcomes to its present state in just over a decade is unprecedented in neurology and possibly in medicine. Our knowledge of NMOSD biology has led to the recognition of wider phenotypes, new disease mechanisms, and thus clinical trials of new and effective treatments. This article aims to update readers on the recent developments in NMOSD with particular emphasis on clinical advances, the 2015 diagnostic criteria, biomarkers, imaging, and therapeutic interventions.
视神经脊髓炎谱系疾病（NMOSD）在短短十几年内从一种罕见、不可治愈且被误解的疾病，演变为一种预后普遍较差的疾病，其在神经病学领域甚至在整个医学领域的发展都是前所未有的。我们对 NMOSD 生物学的认识已经导致了更广泛表型、新疾病机制的出现，从而为新的有效治疗方法的临床试验提供了依据。本文旨在为读者提供 NMOSD 的最新研究进展，特别强调临床进展、2015 年诊断标准、生物标志物、影像学和治疗干预。
